Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors

NCT00902083 is registered in ClinicalTrials.gov with Shenzhen SiBiono GeneTech Co.,Ltd as lead sponsor.

NCT NCT00902083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00902083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors
Lead sponsor
Shenzhen SiBiono GeneTech Co.,Ltd
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2009
Completion date
July 31, 2012
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced oral and maxillofacial malignant tumors